Home Page      Site Map      Newsletter     

• About
  Creabilis

  Mission &
  Strategy

  Investors

   
   
  

• Pipeline

  Projects

   
   
   
  

• Creabilis Science

  MiniPEGylation

  Targets

  Drug Discovery

   
  
•  
   
   

  Contacts

  Information Request

  

Projects

• CT327
  Is being developed as a novel topical treatment for psoriasis.
• CT637
  The CT637 program is aimed at inflammatory and auto-immune disorders.
• CT802
  CT802 is the MiniPEGylated variant of a widely used corticosteroid

Pipeline

• CT802
  CT802 is the MiniPEGylated variant of a widely used corticos ...
• CT327
  Is being developed as a novel topical treatment for psoriasi ...
• CT637
  The CT637 program is aimed at inflammatory and auto-immune ...

more

Sede della società: via Ribes 5, 10010 Colleretto Giacosa (TO), Italy - Ufficio del Registro delle Imprese di Torino numero 08661490014 - Capitale sociale versato 1.500.000,00 Euro - Socio Unico: Creabilis SA